Drug Type Stem cell therapy |
Synonyms NKG2C/DAP12-expressing iNK cells+NKG2C1533 TriKE |
Target |
Mechanism CD33 modulators(Myeloid cell surface antigen CD33 modulators), IL-15Rα agonists(Interleukin-15 receptor subunit alpha agonists), NKG2C modulators(killer cell lectin like receptor C2 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Discovery | US | - | |
Acute Myeloid Leukemia | Discovery | US | - | |
Acute Myeloid Leukemia | Discovery | US | - | |
Acute Myeloid Leukemia | Discovery | US | - |